The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Bayer has cut 1,500 roles – so far

German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.

Cytel Inc acquires the SDS Group

The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...

KI’s new super machine measures brain activity in real-time – “A very expensive hairdo”

Using brand-new, super-advanced equipment, researchers at Karolinska Institutet can now measure brain activity in real-time, with higher resolution than previou...

Individual DNA passport could result in fewer drug side effects

You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...

Studiedeltagare avled efter behandling med crispr-kandidat

En patient som behandlades med amerikanska Intellia Therapeutics genterapi nex-z har avlidit efter att ha vårdats på sjukhus med kraftigt förhöjda levervärden. ...

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Pfizer stämmer Novo Nordisk i miljardstrid om biotechbolag

Budstriden om Metsera trappas upp när Pfizer stämmer både det amerikanska bioteknikbolaget och Novo Nordisk. Kärnfrågan är om Novos bud på 8,5 miljarder dollar ...

New features in ZEISS CALYPSO 2024

ZEISS CALYPSO is your universal software for dimensional metrology applications.

Senzime tar in kapital för fortsatt kommersiell expansion

Medtechbolaget Senzime har beslutat att genomföra en riktad nyemisson. Bolaget planerar att ta in cirka 86 miljoner kronor.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

He saved lives with his theories – was ostracised and ended up in a mental hospital

Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with...

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...

Study names with an attitude – more important than you might think

Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.

Astra Zenecas nya viktminskningsbolag ska bevara muskelmassa

Astra Zeneca har fullföljt en option att köpa det schweiziska start up-bolaget Sixpeaks Bio, som utvecklar fetmabehandlingar.

Raise-In AB

Framgång för Hansa i amerikansk fas III-studie – ”Vi är begeistrade”

Lundbaserade Hansa Biopharmas transplantationsläkemedel imlifidase klarade det primära effektmåttet i en registreringsgrundande fas III-studie i USA.

High biological age is linked to a higher risk of dementia and stroke

It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher tha...

Vicore tar in 782 miljoner för sin lungfibroskandidat

Vicore Pharma har beslutat att ta in upp till 782 miljoner kronor i en företrädesemission för att finansiera fortsatt utveckling av bolagets behandling för idio...

Organize and Manage Digital Classrooms

Create engaging lessons with ZEISS Labscope Teacher.